Primobolan (Methenolone) Clinical Use
Direct Answer
Primobolan (methenolone) is not approved by the FDA for any clinical indication in the United States, and the FDA label provided 1 is actually for primidone (an anticonvulsant), not Primobolan—these are completely different medications that should not be confused.
Critical Clarification: Drug Identity Confusion
Primobolan refers to methenolone (either methenolone acetate oral form or methenolone enanthate injectable form), which is an anabolic-androgenic steroid 2, 3.
Primidone is an entirely different medication—an anticonvulsant used for seizure disorders 1.
The FDA label provided 1 describes primidone dosing for epilepsy, not Primobolan/methenolone.
Historical Clinical Indications (No Longer FDA-Approved)
Methenolone was historically investigated for several conditions but lacks current FDA approval:
Breast Cancer (Historical Use)
- Methenolone enanthate (Primobolan Depot) was studied at doses of 400-1200 mg/week for disseminated breast carcinoma, achieving objective remissions in approximately 19% of patients (8/41 evaluable cases) 2.
- Soft tissue metastases responded best, while liver and brain metastases were unaffected 2.
- The agent was noted to be less virilizing than testosterone propionate but comparable in therapeutic efficiency 2.
- Major adverse effect: Hyperlipoproteinemia type IIa or IIb developed in approximately 43% of treated patients, with one documented myocardial infarction during treatment 4.
Refractory Anemias (Historical Use)
- Methenolone was studied in 19 patients with various refractory anemias, showing remission rates of 50% in pancytopenia (3/6), 50% in bicytopenia (2/4), 20% in refractory anemia with hyperplastic marrow (1/5), and 25% in myelofibrosis (1/4) 3.
- Side effects were reported as negligible in this small series 3.
- A recent 2024 case report suggested methenolone acetate may attenuate bone mineral density decline during anemia treatment in myelodysplastic syndrome 5.
Contemporary Research Applications (Experimental Only)
Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)
- A 2024 randomized rat study demonstrated that methenolone enanthate significantly reduced MRONJ development in bisphosphonate-treated animals undergoing tooth extraction 6.
- Bone exposure rates were 75% in zoledronic acid-only group versus 10% in the methenolone-treated group 6.
- This remains experimental and is not approved for human use in this indication.
Safety Concerns and Monitoring
Cardiovascular and Metabolic Risks
- Hyperlipoproteinemia (types IIa and IIb) occurred in menopausal women receiving methenolone for breast cancer, with complete regression after discontinuation 4.
- The hypercholesterolemia was not dose-related and could not be classified as a bile stasis syndrome 4.
Virilization
- While less virilizing than testosterone propionate, androgenic effects remain a concern, particularly in women 2.
Current Clinical Status
Primobolan (methenolone) has no FDA-approved indications and is not legally prescribed in the United States for medical purposes. Its historical uses in oncology and hematology have been superseded by more effective and safer alternatives. Any contemporary use would be off-label, experimental, or in the context of performance enhancement (which is illegal without a prescription and carries significant health risks).
Common Pitfall to Avoid
- Do not confuse Primobolan (methenolone) with primidone (Mysoline) 1. These are completely different drugs with different indications, mechanisms, and safety profiles. Prescribing primidone when methenolone is intended (or vice versa) would constitute a serious medication error.